申请人:GLAXOSMITHKLINE IP DEV LTD
公开号:WO2018109646A1
公开(公告)日:2018-06-21
The present invention relates to a compound which is (R)-3-(1,4- dimethyl-1 H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-2-ethyl-2,3- dihydropyrido[2,3-f][l,4]oxazepin-4(5H)-yl)methyl)-4-methylphenyl) propanoic acid (I), or a pharmaceutically acceptable salt thereof, in particular, the meglumine salt thereof, a pharmaceutical composition containing the compound and its use as an NRF2 activator.
本发明涉及一种化合物,即(R)-3-(1,4-二甲基-1H-苯并[d][1,2,3]三唑-5-基)-3-(3-(((R)-2-乙基-2,3-二氢喹啉并[2,3-f][1,4]噁唑-4(5H)-基)甲基)-4-甲基苯基)丙酸(I),或其药学上可接受的盐,特别是其美格胺盐,含有该化合物的药物组合物以及其作为 NRF2 激活剂的用途。